Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 3/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.51 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2139474 | 0.99 | HTR7 (0.58) | HTR7SIGMAR1ABCB1TMEM97ABCG2 | |
| SCHEMBL8982683 | 0.97 | SIGMAR1 (0.57) | HTR7SIGMAR1ABCB1TMEM97 | |
| Hydrochloric Acid SCHEMBL4228774 | 0.96 | SIGMAR1 (0.56) | HTR7SIGMAR1ABCB1TMEM97 | |
| SCHEMBL10035614 | 0.89 | HTR7 (0.59) | HTR7SIGMAR1ABCB1TMEM97 | |
| Hydrochloric Acid SCHEMBL2138718 | 0.88 | HTR7 (0.58) | HTR7SIGMAR1ABCB1TMEM97 | |
| SCHEMBL2137287 | 0.88 | HTR7 (0.58) | HTR7SIGMAR1ABCB1TMEM97 | |
| SCHEMBL10035590 | 0.86 | HTR7 (0.61) | HTR7SIGMAR1ABCB1TMEM97 | |
| SCHEMBL10035636 | 0.86 | HTR7 (0.57) | HTR7ABCB1 | |
| SCHEMBL10035567 | 0.86 | HTR7 (0.78) | HTR7SIGMAR1ABCB1ABCG2 | |
| SCHEMBL10035563 | 0.86 | SMN1; SMN2 (0.59) | HTR7SIGMAR1ABCB1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148397-B2 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-04-03 | — | — | US | disclosed |
| US-8148397-B2 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-04-03 | — | — | US | disclosed |
| US-20090088450-A1 | 5-ht7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-04-02 | — | — | US | disclosed |
| US-20090088450-A1 | 5-ht7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-04-02 | — | — | US | disclosed |
| US-7211584-B2 | 5-HT7 receptor ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-01 | — | — | US | disclosed |
| US-7211584-B2 | 5-HT7 receptor ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088450-A1 | 5-ht7 receptor antagonists | HTR7, HTR1A, HTR5A | HTR7 1/4885SIGMAR1 189/4885ABCB1 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.